← Back to all signals
RESEARCH PAPER ANALYSIS

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1-Mutated Acute Myeloid Leukemia.

AI interpretation is pending for this paper.

Open original publication →
PMID40678951
JournalCancer medicine
Publication Date2025-07-01
Ingested2026-08-02 12:04 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: ASXL1 is one of the most frequently mutated genes in acute myeloid leukemia (AML) and retains adverse-risk status in intensively treated cohorts according to 2022 European Leukemia Net (ELN) risk criteria. The therapeutic and prognostic impacts of hypomethylating agents (HMAs) and venetoclax in young adults with ASXL1-mutated AML is unclear. METHODS: Eighty-one patients with ASXL1-mutated AML ≤ 60 years old were retrospectively analyzed. The effects of HMAs plus venetoclax on treatment response and its prognostic value were compared with intensive chemotherapy (IC) and HMAs combined with low-intensity chemotherapy. RESULTS: Intensive chemotherapy independently predicted a worse treatment response (IC vs. HMA + venetoclax, OR = 0.183, 95% CI 0.048-0.693, p = 0.012) and inferior overall survival (OS) (IC vs. HMA + venetoclax, HR = 3.316, 95% CI 1.332-8.255, p = 0.010). After 15 patients with favorable cytogenetics or mutations were excluded, the HMA + venetoclax combination still outweighed IC with respect to treatment response (IC vs. HMA + venetoclax, OR = 0.063, 95% CI 0.012-0.332, p = 0.001) and OS (IC vs. HMA + venetoclax, HR = 3.072, 95% CI 1.216-7.758 p = 0.018) in patients with an adverse risk according to 2022 European Leukemia Net guidelines. Allogeneic hematopoietic stem cell transplantation independently predicted superior OS (HR = 0.234, 95% CI 0.088-0.626, p = 0.004). Additionally, in patients receiving HMAs combined with venetoclax, the G646fs variant of the ASXL1 mutation was associated with a lower complete remission or with an incomplete hematological recovery rate (4/7 vs. 2/19, 42.9% vs. 10.5%, p = 0.026) and worse event-free survival (median, 14.0 months vs. not reach, p = 0.045). CONCLUSION: HMAs and venetoclax could benefit newly diagnosed younger patients with ASXL1-mutated AML.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 [The role of neuroprotection in treating oculomotor neuropathy in a child following endoscopic cystocisternostomy]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 57.6 2 Rivaroxaban prophylaxis and catheter-related thrombosis risk in ambulatory gynecological cancer patients: a retrospective cohort study. Thrombosis journal 76.9 3 Mesenchymal transition as a potential mechanism of late immune evasion in neuroblastoma: a case of late relapse after allogeneic hematopoietic stem cell transplantation. World journal of surgical oncology 88.37 4 Gold Nanoparticles in Retinoblastoma: A Promising Approach for Diagnosis and Treatment. Ocular oncology and pathology 76.5 5 Pars Plana Vitrectomy for Retinal Detachment or Vitreous Haemorrhage after Retinoblastoma Regression: A 20-Year Single-Centre Experience. Ocular oncology and pathology 63.1 6 A Novel Protein Corona-Based Secretome Profiling Assisting Cell Multiomics Analysis. Analytical chemistry 49.7 7 Trefoil Family Factor 1 Expression in the Indian Cohort of Treatment-Naïve Retinoblastoma. Ocular oncology and pathology 66.14 8 mTOR inhibitor everolimus versus conventional chemotherapy in pediatric low-grade gliomas. American journal of cancer research 83.3 9 The scPagwas analysis of single-cell sequencing combined with Bayesian deconvolution with SMR Reveals Tumor Heterogeneity and Predicts Immunotherapy Response in Neuroblastoma. Journal of Cancer 67.34 10 Early Prediction of Cardiomyopathy in Pediatric Cancer Survivors Using Echocardiographic Video-Based Deep Learning. Echocardiography (Mount Kisco, N.Y.) 57.5 11 Novel Compound Heterozygous RECQL4 Pathogenic Variants and Associated Phenotypes in a Chinese Patient With Rothmund-Thomson Syndrome: Case Report and Literature Review. Molecular genetics & genomic medicine 47.5 12 Self-Conscious Emotions and Social Isolation Among Young Adult Cancer Survivors. Psycho-oncology 66.0 13 Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. ESMO open 71.84 14 Fertility preservation counselling in women with cancer: knowledge, preferences, and unmet needs from a cross-sectional survey. Frontiers in endocrinology 66.1 15 Risk prediction model for pegaspargase-associated severe coagulopathy and blood product costs: a single-center retrospective cohort study. Frontiers in pharmacology 63.9 16 The relationship between symptoms of adenomyosis and current ultrasonographic diagnostic criteria. Frontiers in endocrinology 62.4 17 Feasibility of exercise training to address corticosteroid-induced changes in adolescents aged 10+ with lymphoma or leukemia during the first eight weeks of treatment: a pilot study. Frontiers in pediatrics 82.84 18 A predictive model for cytarabine syndrome-associated febrile episodes in children with acute lymphoblastic leukemia. Frontiers in pediatrics 67.4 19 The role of personalised medicine in treating high-risk neuroblastoma in paediatric patients. Oncology reviews 74.0 20 Incidence, severity, and risk factors of platinum-induced ototoxicity in pediatric oncology patients: A multi-center retrospective study. International journal of pediatric otorhinolaryngology 80.72 21 Intracranial Extension of Pott's Puffy Tumor in a Child: CT and MRI Findings. Revista da Sociedade Brasileira de Medicina Tropical 28.5 22 Detecting Isolated Multifocal Leptomeningeal Metastases With 18F-MFBG PET/CT in a Pediatric Patient With High-risk Neuroblastoma. Clinical nuclear medicine 56.4 23 Unusual Isolated Thymic Relapse of Neuroblastoma Detected By 123I-mIBG Scintigraphy in a Pediatric Patient. Clinical nuclear medicine 55.62 24 A Tale of 3 Tracers: Contrasting Uptake Patterns of 18F-FDG, 68Ga-DOTATATE, and 18F-MFBG in a Pediatric Neuroblastoma Patient. Clinical nuclear medicine 57.1 25 Clinical Diagnostic and Prognostic Evaluation of miR-136-5p in Children with Severe Pneumonia: A Case-Control and Cohort Study. Journal of visualized experiments : JoVE 70.8 26 Parents' and health professionals' perspectives on supporting physical activity among children undergoing cancer treatment: A qualitative interview study. European journal of oncology nursing : the official journal of European Oncology Nursing Society 62.74 27 Tests of the testes: markers of testicular function after treatment for pediatric hematological malignancies. The Journal of clinical endocrinology and metabolism 50.74 28 Checkpoint blockade before allogeneic transplantation in pediatric lymphoma warrants a dedicated safety strategy. Comment on: "Immune checkpoint therapy in pediatric and adolescent lymphomas". Haematologica 52.74 29 Forty-Two Cases of Pediatric Giant Cell Tumor of Bone: Insights From a 25-Year Multi-Institutional Cohort. Journal of pediatric orthopedics 63.1 30 Impact of Childbearing and Breastfeeding on Breast Density Change, and Subsequent Breast Cancer Risk in Postmenopausal Women: A Mediation Analysis. International journal of cancer 58.4 31 Neuropathological findings in 2068 individuals with drug-resistant epilepsy based on updated classification systems: A multicenter retrospective cohort study from China. Epilepsia 65.16 32 Clinical Impact of Busulfan Pharmacokinetic Monitoring in Pediatric Allogeneic Transplants: Perspectives from A Transplant Center in A Low- and Middle- Income Country. Pediatric hematology and oncology 63.4
PATIENT-FRIENDLY SUMMARY

Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1-Mutated Acute Myeloid Leukemia.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic